|7.18||-0.1100||-1.51%||Vol 1.51M||1Y Perf -2.80%|
|Oct 4th, 2023 15:50 DELAYED|
|-0.03 -0.41%||- -|
|Target Price||12.19||Analyst Rating||Moderate Buy 1.75|
|Potential %||68.95||Finscreener Ranking||★★★★+ 57.54|
|Insiders Trans % 3/6/12 mo.||-/-43/-85||Value Ranking||★★★+ 53.01|
|Insiders Value % 3/6/12 mo.||-/-39/-99||Growth Ranking||★★★+ 55.09|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-35/-98||Income Ranking||— -|
|Price Range Ratio 52W %||37.20||Earnings Rating||Strong Buy|
|Market Cap||1.03B||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||2nd Nov 2023|
|Estimated EPS Next Report||-0.17|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.44M|
|Avg. Monthly Volume||2.00M|
|Avg. Quarterly Volume||2.11M|
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) stock closed at 7.29 per share at the end of the most recent trading day (a -2.02% change compared to the prior day closing price) with a volume of 1.56M shares and market capitalization of 1.03B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 294 people. Aurinia Pharmaceuticals Inc CEO is Peter S. Greenleaf.
The one-year performance of Aurinia Pharmaceuticals Inc stock is -2.8%, while year-to-date (YTD) performance is 68.75%. AUPH stock has a five-year performance of 15.71%. Its 52-week range is between 4.07 and 12.43, which gives AUPH stock a 52-week price range ratio of 37.20%
Aurinia Pharmaceuticals Inc currently has a PE ratio of -9.10, a price-to-book (PB) ratio of 2.53, a price-to-sale (PS) ratio of 10.13, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -29.11%, a ROC of -31.64% and a ROE of -34.16%. The company’s profit margin is -77.78%, its EBITDA margin is -87.50%, and its revenue ttm is $105.60 Million , which makes it $0.74 revenue per share.
Of the last four earnings reports from Aurinia Pharmaceuticals Inc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.17 for the next earnings report. Aurinia Pharmaceuticals Inc’s next earnings report date is 02nd Nov 2023.
The consensus rating of Wall Street analysts for Aurinia Pharmaceuticals Inc is Moderate Buy (1.75), with a target price of $12.19, which is +68.95% compared to the current price. The earnings rating for Aurinia Pharmaceuticals Inc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aurinia Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aurinia Pharmaceuticals Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 13.55, ATR14 : 0.39, CCI20 : -129.28, Chaikin Money Flow : -0.31, MACD : -0.53, Money Flow Index : 11.02, ROC : -17.53, RSI : 24.41, STOCH (14,3) : 3.50, STOCH RSI : 0.00, UO : 32.29, Williams %R : -96.50), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aurinia Pharmaceuticals Inc in the last 12-months were: George Mclean Milne (Buy at a value of $178 284), Joseph M. Miller (Sold 11 296 shares of value $100 986 ), Matthew Donley (Buy at a value of $93 200), Michael R. Martin (Buy at a value of $154 800), Scott Michael Habig (Buy at a value of $25 075), Stephen P. Robertson (Sold 19 402 shares of value $173 454 )
Mon, 07 Aug 2023 14:40 GMT Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Pharvaris (PHVS)- TipRanks. All rights reserved.
Sat, 05 Aug 2023 01:46 GMT Aurinia Pharmaceuticals (AUPH) Gets a Buy from RBC Capital- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.